Kantonsspital St.Gallen

Abbvie M 14-347

Jan Borovicka, Remus Frei & Gian Marco Semadeni

abstract A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and
Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease
type of project clinical studies
status completed
start of project 2015
end of project 2017
study design Investigational Products: Adalimumab (40 mg/0.8 ml)
Doses: Open-Label Period
40 mg every other week or 40 mg ew for subjects whose disease is not
controlled on 40 mg eow beginning at Weeks 0 until Week 40
Mode of Administration: Subcutaneous (SC)
Duration of
responsible person Prof. Jan Borovicka